The Pharmacist

APRIL 15, 2024

The NHS national booking system for spring Covid-19 vaccination bookings via pharmacies in England is now open. They include adults aged 75 or over as of 30 June 2024, residents in care homes for older adults, and individuals who are immunosuppressed. Those eligible to book appointments are able to do so for next week.

Vaccines 111

Vaccines 111

Pharmaceutical Technology

OCTOBER 13, 2023

The Phase IIb SurVaxM vaccine study will enrol 265 patients and has an estimated completion date in Q2 2024.

Vaccines 111

Vaccines 111

Pharmaceutical Business Review

SEPTEMBER 16, 2024

This vaccine is intended for individuals aged 12 and above and is now stocked at pharmacies including CVS Pharmacy, Walgreens, Rite Aid among others. The vaccine has been granted Emergency Use Authorization by the US Food and Drug Administration on 30 August 2024. Our vaccine targets JN.1, 1.1.” “Our vaccine targets JN.1,

Vaccines 111

Vaccines Independent Pharmacies 111

Pharmaceutical Technology

SEPTEMBER 12, 2023

adapted monovalent Covid-19 vaccine, COMIRNATY 2023-2024 Formulation. The US FDA has approved Pfizer and BioNTech’s sBLA for Omicron XBB.1.5-adapted

Vaccines 111

Vaccines 111

Express Pharma

OCTOBER 16, 2024

Messenger ribonucleic acid (mRNA)-based innovator pharmaceuticals saw a staggering 800 per cent increase in licensing agreement deal values from 2019 to 2024YTD, driven by the remarkable success of mRNA vaccines during the COVID-19 pandemic. billion in July 2024. billion in 2030. Bristol Myers Squibb formed a multi-year, $1.87

Vaccines 104

Vaccines Immunity Immunization Diabetes 104

Express Pharma

AUGUST 27, 2024

Indian Immunologicals Limited (IIL) has announced the development of a live-attenuated, needle-free intranasal booster vaccine against SARS-CoV-2. The vaccine was created using codon deoptimization technology in collaboration with Griffith University, Australia. The danger due to COVID-19 is still not over.

Vaccines 104

Vaccines Immunization Immunity Communication 104

Express Pharma

JUNE 6, 2024

Stakeholders are invited to provide feedback on CDSCO draft guidance within 15 days from the notice’s issuance On May 29, 2024 a draft of the revised “Guidance for Industry on Pharmacovigilance Requirements for Human Vaccines” was released for public consultation by Central Drug Standard Control Organisation (CDSCO).

Vaccines 105

Vaccines Documentation 105

Pharmaceutical Business Review

SEPTEMBER 6, 2024

This recommendation will aid in the potential authorisation of the vaccine for use in individuals aged six months and older to prevent Covid-19 in the upcoming 2024-2025 autumn/winter season. 1 family of Omicron subvariants for the upcoming vaccination campaign. Moderna’s vaccine targeting the JN.1

Vaccines 104

Vaccines 104

Express Pharma

OCTOBER 25, 2023

With influenza season well underway, vaccination campaigns are in full force in the northern hemisphere. This will reshape the global influenza vaccine market for the upcoming seasons, says GlobalData. Kurdach continues, “When the actual composition of vaccines will revert to trivalent formulations remains another question.

Vaccines 98

Vaccines 98

The Pharmacist

JUNE 24, 2024

‘A number’ of community pharmacies will be commissioned by NHS England (NHSE) to provide the respiratory syncytial virus (RSV) vaccine to older adults from this autumn.

Vaccines 91

Vaccines Community Pharmacies 91

The Pharmacist

JUNE 14, 2024

Pharmacies have been advised they should order alternative vaccines from an approved list, after Sanofi has said its recombinant quadrivalent influenza vaccine (QIVr) would not be available for this year’s flu programme.

Vaccines 88

Vaccines 88

Express Pharma

SEPTEMBER 12, 2024

Indian Immunologicals (IIL), a vaccine manufacturer, has signed a Memorandum of Agreement (MoA) with the Indian Council of Medical Research (ICMR) to develop India’s first codon de-optimized live attenuated Zika vaccine. According to the Ministry of Health, as of July 22, 2024, there have been 537 registered Zika cases in the country.

Vaccines 105

Vaccines Hospitals 105

pharmaphorum

MARCH 7, 2022

The World Health Organization (WHO) announced the opening of a global biomanufacturing hub located in South Korea to provide training to low- and middle-income countries seeking to produce vaccines and other biologics, such as insulin and monoclonal antibodies. . of individuals in low-income countries have received their first dose.

Vaccines 98

Vaccines 98

Pharmaceutical Technology

FEBRUARY 21, 2023

Pfizer and BioNTech’s Covid-19 vaccine, Comirnaty, had a phenomenal year with forecast sales of $37bn in 2022. Comirnaty is the leading prophylactic vaccine for Covid-19 and is expected to generate an additional $2.8bn in sales in 2022 compared to GlobalData’s H1 2022 forecast. Comirnaty is the first globally approved Covid-19 vaccine.

Vaccines 98

Vaccines 98

Express Pharma

JUNE 3, 2024

mRESVIA is Moderna’s second approved product and reportedly the only RSV vaccine available in single-dose pre-filled syringes Moderna, announced that the U.S. This approval is also the first time an mRNA vaccine has been approved for a disease other than COVID-19. The primary analysis with 3.7 per cent (95.88 per cent CI 66.0

Vaccines 81

Vaccines Adverse Reactions Packaging 81

pharmaphorum

SEPTEMBER 27, 2022

Ben Hargreaves finds that the next step to enhance these treatments further could be to find synergies with emerging therapies employing similar modes of action, such as therapeutic cancer vaccines. One area that is becoming more widely discussed with the potential to be added to this group is that of therapeutic cancer vaccines.

Vaccines 97

Vaccines Immunity Immunization 97

Pharmacy Times

OCTOBER 20, 2023

An overview of updated CDC ACIP recommendations for COVID-19 vaccines available through commercial channels for the 2023-2024 season.

Vaccines 49

Vaccines 49

pharmaphorum

DECEMBER 16, 2022

Ben Hargreaves discovers why some have referred to the distribution of COVID-19 vaccines and treatments as a form of apartheid. Vaccine access for a price. Tendayi Achium, labelled the response by the global community as a form of “vaccine apartheid,” a suggestion echoed by the organisation’s director general.

Vaccines 96

Vaccines Pharmaceutical Manufacturing Labelling Compounding 96

Pharmacy Times

SEPTEMBER 13, 2023

The CDC emphasized the need for protein-based vaccine options in endorsing a vote by the Advisory Committee on Immunization Practices for the universal recommendation of the 2023-2024 monovalent, XBB containing COVID-19 vaccines.

Vaccines 55

Vaccines Immunity Immunization 55

Pharmaceutical Technology

OCTOBER 4, 2023

The US FDA has amended the EUA of Novavax’s adjuvanted Covid-19 vaccine (NVX-CoV2601) to incorporate the 2023-2024 formula.

Vaccines 69

Vaccines 69

Pharmacy Times

OCTOBER 26, 2024

With COVID-19, influenza, respiratory syncytial virus (RSV), and other viruses now circulating, the time for pharmacists to get up to date on the latest vaccine recommendations is now.

Vaccines 52

Vaccines 52

pharmaphorum

MARCH 11, 2022

After a period where vaccine development had fallen away, suddenly it is back in the limelight. However, for those individuals working on vaccine development, the pandemic has proven to be a validation of the important work being carried out in the field. billion from its vaccine in 2021. The ‘poor relation’.

Vaccines 81

Vaccines Diabetes Hospitals 81

PharmaTech

MAY 25, 2024

In an ASGCT Panel on nucleic acid- and cell-based vaccines in oncology, work on a personalized mRNA vaccine was highlighted.

Vaccines 52

Vaccines 52

pharmaphorum

AUGUST 9, 2024

Personalized Cancer Vaccine Summit Mike.Hammerton Fri, 09/08/2024 - 08:36 Bookmark this

Vaccines 52

Vaccines 52

Big Molecule Watch

SEPTEMBER 3, 2024

On August 22, Moderna announced that FDA approved its supplemental Biologics License Application (“sBLA”) for a new formula of their COVID-19 vaccine, SPIKEVAX®, for individuals 12 years old and above. Emergency Use Authorization (“EUA”) was also granted for the updated vaccine for individuals aged 6 months to 11 years old.

Vaccines 59

Vaccines Hospitals 59

Pharmaceutical Business Review

SEPTEMBER 2, 2024

The Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) [NVX-CoV2705] is now authorised for active immunisation against Covid-19. Following the EUA, the vaccine is also recommended by the US Centers for Disease Control and Prevention (CDC). Our updated vaccine targets JN.1, 1.” “Our updated vaccine targets JN.1,

Vaccines 59

Vaccines Adverse Reactions Immunity Immunization 59

Pharmaceutical Business Review

AUGUST 9, 2024

of the contract amount, will be produced and invoiced in 2024. Additionally, the contract includes around $17m for additional services from 2025 to 2027, which encompasses the storage of vaccine doses within the US. The vaccine has also received emergency use authorisation in other regions during the mpox outbreak.

Vaccines 59

Vaccines 59

Pharmaceutical Business Review

AUGUST 26, 2024

vaccine efficacy against RSV lower respiratory tract disease after a median follow-up of 3.7 months showed that mRNA-1345 maintained its efficacy, demonstrating a sustained vaccine efficacy of 63.3% The vaccine also showed 74.6% The trial’s primary analysis indicated an 83.7% Further analysis with a median follow-up of 8.6

Vaccines 59

Vaccines 59

Pharmafile

MAY 13, 2024

Moderna has announced that the US Food and Drug Administration (FDA) has shared that it will not complete its review of the Biologics License Agreement (BLA) for mRNA-1345 by its Prescription Drug User Fee Act (PDUFA) date of 12 May 2024. The post Moderna shares update on RSV vaccine appeared first on Pharmafile.

Vaccines 52

Vaccines 52

Pharmaceutical Technology

MAY 22, 2023

The ongoing patent litigation between CureVac and Pfizer /BioNTech will move to a court in Virginia following a request from Curevac, potentially bringing forward the trial date to sometime in 2024. The Covid-19 pandemic saw a proliferation in novel vaccine technologies being produced rapidly.

Vaccines 116

Vaccines Communication 116

Pharmacy Times

OCTOBER 4, 2024

Significant polarization surrounding COVID-19 vaccinations in late 2020 and early 2021 looked to have had an impact in increasing vaccine hesitancy.

Vaccines 52

Vaccines 52

Pharmaceutical Technology

FEBRUARY 14, 2023

The US Department of Health and Human Services (HHS) and the Department of Defense have modified their existing agreement with Novavax to secure additional doses of the Covid-19 vaccine, Adjuvanted (NVX-CoV2373). million additional doses of its Covid-19 vaccine. Under the modified deal, Novavax will deliver up to 1.5

Vaccines 64

Vaccines 64

Pharmacy Times

SEPTEMBER 25, 2023

For community pharmacists, cooler temperatures, school buses on the roads and Friday night football are not just signs of a changing season – they are indicators that patients will soon be seeking vaccinations for the 2023-2024 respiratory illness season.

Vaccines 59

Vaccines Immunity Immunization 59

Pharmacy Times

JANUARY 22, 2024

The schedule includes RSV vaccination, along with updated versions of the COVID-19 vaccine.

Vaccines 50

Vaccines Immunity Immunization 50

Pharmaceutical Technology

SEPTEMBER 12, 2024

The vaccine manufacturer said it could also supply 13 million doses by YE 2025 to meet requests by Africa CDC and UNICEF.

Vaccines 52

Vaccines 52

PharmExec

NOVEMBER 8, 2024

At the Financial Times’ Global Pharma and Biotech Summit 2024, a panel discussed the potential of mRNA technology in developing cancer vaccines amid distrust from the public.

Vaccines 52

Vaccines 52

Pharmacy Times

OCTOBER 3, 2023

NVX-CoV2601 vaccine adjuvanted 2023-2024 formula granted EUA for the prevention of COVID-19 in those 12 years of age and older.

Vaccines 58

Vaccines 58